Family Medicine & Primary Care Review
eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
3/2025
vol. 27
 
Share:
Send email
Share:
CONTINUOUS MEDICAL EDUCATION (CME)
Review paper

Vaccination against shingles. Recommendations of a group of experts from Polish scientific societies – update 2025

Ernest Kuchar
1
,
Justyna Ledwoch
2
,
Jacek Bil
3
,
Małgorzata Czajkowska-Malinowska
4
,
Robert Gil
3
,
Magdalena Kocot-Kępska
5
,
Irina Kowalska
6
,
Magdalena Krajewska
7, 8
,
Alina Kułakowska
9
,
Agnieszka Mastalerz-Migas
10
,
Joanna Narbutt
11
,
Monika Nojszewska
12
,
Anna Przeklasa-Muszyńska
5
,
Konrad Rejdak
13
,
Lidia Rudnicka
14
,
Leszek Szenborn
15
,
Jacek Szepietowski
8, 16
,
Krzysztof Tomasiewicz
17
,
Jacek Wysocki
18, 19
,
Agnieszka Zmysłowska
20
,
Aneta Nitsch-Osuch
21

  1. Department of Pediatrics with Clinical Observation Unit, Medical University of Warsaw, Warsaw, Poland; Polish Society of Vaccinology
  2. Polish Society of Family Medicine, Poland
  3. Cardiology Department, National Medical Institute of the Internal Affairs and Administration Ministry, Warsaw, Poland
  4. Department of Lung Diseases and Respiratory Failure, Kuyavian-Pomeranian Pulmonology Center, Bydgoszcz, Poland; Polish Respiratory Society
  5. Department for Pain Research and Treatment, Chair of Anesthesiology and Intensive Care, Medical College, Jagiellonian University, Cracow, Poland; Polish Association for the Study of Pain
  6. Department of Internal Medicine and Metabolic Diseases, Medical University of Bialystok, Bialystok, Poland
  7. Division of Nephrology, Transplantology and Clinical Immunology, 4th Military Clinical Hospital with Polyclinic SPZOZ, Wroclaw, Poland
  8. Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland
  9. Department of Neurology, Medical University of Bialystok Bialystok, Poland
  10. Department of Family Medicine, Wroclaw Medical University, Wroclaw, Poland; Polish Society of Family Medicine
  11. Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland
  12. Department of Neurology, Medical University of Warsaw, Warsaw, Poland
  13. Chair and Department of Neurology, Medical University of Lublin, Lublin, Poland
  14. Department of Dermatology, Medical University of Warsaw, Warsaw, Poland; Polish Dermatological Society
  15. Department of Pediatrics and Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland; Polish Society of Vaccinology
  16. Department of Dermato-Venereology, 4th Military Clinical Hospital with Polyclinic SPZOZ, Wroclaw, Poland
  17. Department of Infectious Diseases and Hepatology USK-1, Medical University of Lublin, Lublin, Poland
  18. Department of Infectious Diseases with Observation Unit the Specialist Hospital of Mother and Child Health Care in Poznan, Poznan, Poland
  19. Department of Preventive Medicine, Medical University of Poznan, Poznan, Poland; The Polish Society of Vaccinology
  20. Department of Clinical Genetics, Medical University of Lodz, Lodz, Poland
  21. Department of Social Medicine and Public Health, Medical University of Warsaw, Warsaw, Poland; Polish Society of Family Medicine, Poland
Family Medicine & Primary Care Review 2025; 27(3): 360-369
DOI: https://doi.org/10.5114/fmpcr.2025.153664
Online publish date: 2025/09/29
Article file
- 16 FM&PCR 3 25 - CME R - Kuchar - 1932 - Vaccination against shingles.pdf  [0.33 MB]
Get citation
 
PlumX metrics:
 
1. Centers for Disease Control and Prevention. Clinical Overview of Herpes Zoster (Shingles) [cited 06.05.2025]. Available from URL: https://www.cdc.gov/shingles/hcp/clinical-overview/?CDC_AAref_Val=https://www.cdc.gov/shingles/hcp/clinical-overview.html.
2. Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol 2010; 342: 341–357, doi: 10.1007/82_2010_31.
3. Patil A, Goldust M, Wollina U. Herpes zoster: A Review of Clinical Manifestations and Management. Viruses 2022; 14(2): 192, doi: 10.3390/v14020192.
4. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014; 4(6): e004833, doi: 10.1136/bmjopen-2014-004833.
5. Gross GE, Eisert L, Doerr HW, et al. S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia. J Dtsch Dermatol Ges 2020; 18(1): 55–78, doi: 10.1111/ddg.14013.
6. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82(11): 1341–1349, doi: 10.4065/82.11.1341 [published correction appears in Mayo Clin Proc 2008; 83(2): 255].
7. Marra F, Ruckenstein J, Richardson K. A meta-analysis of stroke risk following herpes zoster infection. BMC Infect Dis 2017; 17(1): 198, doi: 10.1186/s12879-017-2278-z.
8. Tseng HF, Bruxvoort K, Ackerson B, et al. The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults ≥ 50 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence. J Infect Dis 2020; 222(5): 798–806, doi: 10.1093/infdis/jiz652.
9. Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection 2014; 42(2): 325–334, doi: 10.1007/s15010-013-0550-8.
10. Lin SY, Liu JH, Lin CL, et al. A comparison of herpes zoster incidence across the spectrum of chronic kidney disease, dialysis and transplantation. Am J Nephrol 2012; 36(1): 27–33, doi: 10.1159/000339004.
11. Kuchar E, Rudnicka L, Kocot-Kępska M, et al. Szczepienie przeciwko półpaścowi. Zalecenia grupy ekspertów Polskiego Towarzystwa Wakcynologii, Polskiego Towarzystwa Medycyny Rodzinnej, Polskiego Towarzystwa Dermatologicznego, Polskiego Towarzystwa Badania Bólu i Polskiego Towarzystwa Neurologicznego. Med Prakt 2023; 5: 64–72 (in Polish).
12. Albrecht P, Patrzałek M, Goryński P. Zagrożenie półpaścem i jego powikłaniami w Polsce i na świecie w zależności od wieku [cited 06.05.2025]. Available from URL: http://www.przeglepidemiol.pzh.gov.pl/zagrozenie-polpascem-i-jego-powiklaniami-w-polsce-w-zaleznosci-od-wieku?lang=pl (in Polish).
13. CEZ. Zaburzenia psychiczne związane z połogiem oraz półpasiec i nerwobóle po przebytym półpaścu [cited 06.05.2025]. Available from URL:  https://ezdrowie.gov.pl/portal/home/badania-i-dane/zdrowe-dane/zestawienia/polpasiec-nerwobole-zaburzenia-psychiczne-zwiazane-z-pologiem (in Polish).
14. Charakterystyka Produktu Leczniczego Shingrix [cited 06.05.2025]. Available from URL: www.ema.europa.eu/en/documents/product-information/shingrix-epar-product-information_pl.pdf (in Polish).
15. Anderson TC, Masters NB, Guo A, et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ?19 Years: Recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71: 80–85.
16. Centers for Disease Control and Prevention. Shingles Vaccine Recommendations [cited 06.05.2025]. Available from URL: https://www.cdc.gov/shingles/hcp/vaccine-considerations/index.html.
17. Strezova A, Díez Domingo J, Cunningham AL, et al. Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications. EClinicalMedicine 2025; 83: 103241, doi: 10.1016/j.eclinm.2025.103241.
18. Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep 2018; 67: 103–108, doi: 10.15585/mmwr.mm6703a5.
19. López-Fauqued M, Campora L, Delannois F, et al. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. Vaccine 2019; 37(18): 2482–2493, doi: 10.1016/j.vaccine.2019.03.043.
20. Stefanizzi P, Moscara L, Palmieri C, et al. Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23. Vaccine 2024; 42(12): 2966–2974, doi: 10.1016/j.vaccine.2024.03.024.
21. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372(22): 2087–2096, doi: 10.1056/NEJMoa1501184.
22. Boutry C, Hastie A, Diez-Domingo J, et al. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70. Clin Infect Dis 2022; 74(8): 1459–1467, doi: 10.1093/cid/ciab629.
23. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med 2016; 375(11): 1019–1032, doi: 10.1056/NEJMoa1603800.
24. Bastidas A, Serna J, de la, El Idrissi M, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA 2019; 322: 123–133.
25. Dagnew AF, Ilhan O, Lee WS, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis 2019; 19(9): 988–1000, doi: 10.1016/S1473-3099(19)30163-X [published correction appears in Lancet Infect Dis 2020; 20(1): e1, doi: 10.1016/S1473-3099(19)30671-1].
26. Vink P, Delgado Mingorance I, Maximiano Alonso C, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. Cancer 2019; 125(8): 1301–1312, doi: 10.1002/cncr.31909 [published correction appears in Cancer 2020; 126(12): 2941, doi: 10.1002/cncr.32842].
27. Vink P, Ramon Torrell JM, Sanchez Fructuoso A, et al. Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial. Clin Infect Dis 2020; 70(2): 181–190, doi: 10.1093/cid/ciz177.
28. Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis 2015; 211(8): 1279–1287, doi: 10.1093/infdis/jiu606.
29. López-Fauqued M, Co-van der Mee M, Bastidas A, et al. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials. Drug Saf 2021; 44(7): 811–823, doi: 10.1007/s40264-021-01076-w.
30. Curran D, Kim JH, Matthews S, et al. Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals. J Am Geriatr Soc 2021; 69(3): 744–752, doi: 10.1111/jgs.16917.
31. Satyam VR, Li PH, Reich J, et al. Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2020; 65(10): 2986–2991, doi: 10.1007/s10620-019-06016-4.
32. Desai A, Hashash JG, Kochhar GS, et al. Recombinant Zoster Vaccine [RZV] is Effective in Patients with Inflammatory Bowel Disease: A US Propensity Matched Cohort Study. J Crohns Colitis 2024; 18(6): 828–835, doi: 10.1093/ecco-jcc/jjae008.
33. Stevens E, Weinblatt ME, Massarotti E, et al. Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center’s Experience With 400 Patients. ACR Open Rheumatol 2020; 2(6): 357–361, doi: 10.1002/acr2.11150.
34. Komunikat Głównego Inspektora Sanitarnego z dnia 31 października 2024 r. w sprawie Programu Szczepień Ochronnych na rok 2025 (Dz. Urz. Min. Zdr. 2024 poz. 93) (in Polish).
35. Obwieszczenie Ministra Zdrowia z dnia 19 marca 2025 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 kwietnia 2025 r. [cited 06.05.2025]. Available from URL: https://www.gov.pl/web/zdrowie/obwieszczenie-ministra-zdrowia-z-dnia-19-marca-2025-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych-na-1-kwietnia-2025-r (in Polish).
36. WHO position paper on herpes zoster vaccines – July 2025. WER 2025; 27/28: 265–284.
37. Winthrop KL, Curtis JR, Lindsey S, et al. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. Arthritis Rheumatol 2017; 69(10): 1960–1968, doi: 10.1002/art.40189.
38. Esteban-Vasallo MD, Domínguez-Berjón MF, Gil-Prieto R, et al. Sociodemographic characteristics and chronic medical conditions as risk factors for herpes zoster: a population-based study from primary care in Madrid (Spain). Hum Vaccin Immunother 2014; 10(6): 1650–1660, doi: 10.4161/hv.28620.
39. Södergren E, Mårdberg K, Nishimwe M, et al. Incidence and Burden of Herpes Zoster in Sweden: A Regional Population-Based Register Study. Infect Dis Ther 2024; 13(1): 121–140, doi: 10.1007/s40121-023-00902-1.
40. Yanni EA, Ferreira G, Guennec M, et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012. BMJ Open 2018; 8: e020528, doi: 10.1136/bmjopen-2017-020528.
41. Qian J, Lassere MN, Heywood AE, et al. Use of disease-modifying antirheumatic drugs and the subsequent risk of herpes zoster in older adults. Rheumatology 2021; 60(11): 5042–5051, doi: 10.1093/rheumatology/keab538.
42. Muñoz-Quiles C, López-Lacort M, Díez-Domingo J, et al. Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009–2014. BMC Infect Dis 2020; 20(1): 905, doi: 10.1186/s12879-020-05648-6.
43. Singer D, Thompson-Leduc P, Poston S, et al. Incidence of Herpes Zoster in Patients with Rheumatoid Arthritis in the United States: A Retrospective Cohort Study. J Rheumatol 2023; 50(7): 873–880, doi: 10.3899/jrheum.220986.
44. Alves C, Penedones A, Mendes D, et al. The Risk of Infections Associated with JAK Inhibitors in Rheumatoid Arthritis: A Systematic Review and Network Meta-analysis. J Clin Rheumatol 2022; 28(2): e407–e414, doi: 10.1097/RHU.0000000000001749.
45. Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med 2020; 382(3): 211–221, doi: 10.1056/NEJMoa1912196.
46. Henze L, Buhl C, Sandherr M, et al. Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus. Ann Hematol 2022; 101(3): 491–511, doi: 10.1007/s00277-021-04746-y.
47. Hansson E, Forbes HJ, Langan SM, et al. Herpes zoster risk after 21 specific cancers: population-based case-control study. Br J Cancer 2017; 116(12): 1643–1651, doi: 10.1038/bjc.2017.124.
48. Kho MML, Roest S, Bovée DM, et al. Herpes Zoster in Solid Organ Transplantation: Incidence and Risk Factors. Front Immunol 2021; 12: 645718, doi: 10.3389/fimmu.2021.645718.
49. Mareque M, Oyagüez I, Morano R, et al. Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain. Public Health 2019; 167: 136–146, doi: 10.1016/j.puhe.2018.10.015.
50. Steinmann M, Lampe D, Grosser J, et al. Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and heterogeneity patterns. Infection 2024; 52(3): 1009–1026, doi: 10.1007/s15010-023-02156-y.
51. Lai SW, Lin CL, Liao KF. Splenectomy associated with increased risk of herpes zoster in a population-based cohort study. Int J Evid Based Healthc 2020; 18(2): 241–246, doi: 10.1097/XEB.0000000000000206.
52. Lindsay D, Cunningham-Rundles C, Fuleihan RL, et al. Incidence of reactivated Herpes Zoster (shingles) in patients with Primary Immune Deficiency. J Allergy Clin Immunol 2018; 141(2): AB21.
53. Liu B, Heywood AE, Reekie J, et al. Risk factors for herpes zoster in a large cohort of unvaccinated older adults: a prospective cohort study. Epidemiol Infect 2015; 143(13): 2871–2881, doi: 10.1017/S0950268814003653.
54. Blennow O, Fjaertoft G, Winiarski J, et al. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis – the incidence remains high. Biol Blood Marrow Transplant 2014; 20(10): 1646–1649, doi: 10.1016/j.bbmt.2014.06.002.
55. Kim DH, Messner H, Minden M, et al. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis 2008; 10(2): 90–98, doi: 10.1111/j.1399-3062.2007.00247.x.
56. Baumrin E, Izaguirre NE, Bausk B, et al. Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation. Blood Adv 2021; 5(6): 1585–1593, doi: 10.1182/bloodadvances.2020003749.
57. Karakulska-Prystupiuk E, Feliksbrot-Bratosiewicz M, Król M, et al. Prevalence of VZV Reactivation and Effectiveness of Vaccination with Recombinant Adjuvanted Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Recipients – A Single-Center Analysis. Infect Dis Rep 2025; 17(3): 48, doi: 10.3390/idr17030048.
58. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58(3): e44–e100, doi: 10.1093/cid/cit684 [published correction appears in Clin Infect Dis 2014; 59(1): 144].
59. Kamboj M, Bohlke K, Baptiste DM, et al. Vaccination of Adults with Cancer: ASCO Guideline. J Clin Oncol 2024; 42(14): 1699–1721, doi: 10.1200/JCO.24.00032.
60. Kambo M, Shah MK. Vaccination of the stem cell transplant (SCT) recipient and the hematologic malignancy patient. Infect Dis Clin North Am 2019; 33: 593.
61. Kroger A, Bahta L, Hunter P. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention [cited 06.05.2025]. Available from URL: https://stacks.cdc.gov/view/cdc/124166.
62. Shahid Z, Jain T, Dioverti V, et al. Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies. Transplant Cell Ther 2024; 30(10): 955–969, doi: 10.1016/j.jtct.2024.07.018.
63. Majeed A, Harris Z, Brucks E, et al. Revisiting Role of Vaccinations in Donors, Transplant Recipients, Immunocompromised Hosts, Travelers, and Household Contacts of Stem Cell Transplant Recipients. Biol Blood Marrow Transplant 2020; 26(2): e38–e50, doi: 10.1016/j.bbmt.2019.10.030.
64. Chong PP, Avery RK. A Comprehensive Review of Immunization Practices in Solid Organ Transplant and Hematopoietic Stem Cell Transplant Recipients. Clin Ther 2017; 39(8): 1581–1598, doi: 10.1016/j.clinthera.2017.07.005.
65. Hirzel C, L’Huillier AG, Ferreira VH, et al. Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients. Am J Transplant 2021; 21(6): 2246–2253, doi: 10.1111/ajt.16534.
66. Shimizuguchi T, Sekiya N, Hara K, et al. Radiation therapy and the risk of herpes zoster in patients with cancer. Cancer 2020; 126(15): 3552–3559, doi: 10.1002/cncr.32926.
67. Singer D, Thompson-Leduc P, Gupta D, et al. Incidence and risk of herpes zoster in patients with ulcerative colitis and Crohn’s disease in the USA. Gastroenterol Rep (Oxf) 2023; 11: goad016, doi: 10.1093/gastro/goad016.
68. Ning L, Liu R, Li S, et al. Increased risk of herpes zoster infection in patients with inflammatory bowel disease: a meta-analysis of cohort studies. Eur J Clin Microbiol Infect Dis 2020; 39(2): 219–227, doi: 10.1007/s10096-019-03706-9.
69. Yun H, Yang S, Chen L, et al. Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. Arthritis Rheumatol 2016; 68(9): 2328–2337, doi: 10.1002/art.39670.
70. Chen J, Shin JY, Bea S, et al. Burden of Herpes Zoster in Individuals with Chronic Conditions in the Republic of Korea: A Nationwide Population-Based Database Study. Open Forum Infect Dis 2024; 11(10): ofae535, doi: 10.1093/ofid/ofae535.
71. Lai SW, Liao KF, Lin CL, et al. Association between cirrhosis and herpes zoster in a cohort study in Taiwan. Int J Clin Pract 2021; 75(11): e14677, doi: 10.1111/ijcp.14677.
72. Jeon D, Kim YJ, Kim S, et al. Liver Cirrhosis Increases the Risk of Herpes Zoster: A Nationwide Population-Based Cohort Study. Am J Gastroenterol 2023; 118(9): 1592–1600, doi: 10.14309/ajg.0000000000002209.
73. Yu CW, Chen CH, Cheng YC, et al. Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease. Eur J Med Res 2023; 28(1): 550, doi: 10.1186/s40001-023-01524-6.
74. Veetil BM, Myasoedova E, Matteson EL, et al. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis Care Res (Hoboken) 2013; 65(6): 854–861, doi: 10.1002/acr.21928.
75. Kwan A, Rayes HA, Lazova T, et al. Herpes zoster in SLE: prevalence, incidence and risk factors. Lupus Sci Med 2022; 9(1): e000574, doi: 10.1136/lupus-2021-000574.
76. Batram M, Witte J, Schwarz M, et al. Burden of Herpes Zoster in Adult Patients with Underlying Conditions: Analysis of German Claims Data, 2007–2018. Dermatol Ther (Heidelb) 2021; 11(3): 1009–1026, doi: 10.1007/s13555-021-00535-7.
77. Qian J, Lassere MN, Heywood AE, et al. Use of disease-modifying antirheumatic drugs and the subsequent risk of herpes zoster in older adults. Rheumatology (Oxford) 2021; 60(11): 5042–5051, doi: 10.1093/rheumatology/keab538.
78. Min C, Yoo DM, Kim M, et al. Increased risk of herpes zoster in patients with psoriasis: A longitudinal follow-up study using a national sample cohort. Australas J Dermatol 2021; 62(2): 183–189, doi: 10.1111/ajd.13534.
79. Muñoz-Quiles C, López-Lacort M, Ampudia-Blasco FJ, et al. Risk and impact of herpes zoster on patients with diabetes: A population-based study, 2009–2014. Hum Vaccin Immunother 2017; 13(11): 2606–2611, doi: 10.1080/21645515.2017.1368600.
80. Yamaoka-Tojo M, Tojo T. Herpes Zoster and Cardiovascular Disease: Exploring Associations and Preventive Measures through Vaccination. Vaccines (Basel) 2024; 12(3): 252, doi: 10.3390/vaccines12030252.
81. Tanaka K, Kimura E, Oryoji K, et al. Hypertension and dyslipidemia are risk factors for herpes zoster in patients with rheumatoid arthritis: a retrospective analysis using a medical information database. Rheumatol Int 2021; 41(9): 1633–1639, doi: 10.1007/s00296-021-04889-1.
82. Chuanchaiyakul N, Thongtang N, Rattanaumpawan P. Cumulative incidence of and risk factors for herpes zoster among patients with diabetes mellitus: Results from a 10-year nested case-control study. J Diabetes Complications 2022; 36(5): 108168, doi: 10.1016/j.jdiacomp.2022.108168 [published correction appears in J Diabetes Complications 2024; 38(2): 108674, doi: 10.1016/j.jdiacomp.2023.108674].
83. Wu PH, Lin YT, Lin CY, et al. A nationwide population-based cohort study to identify the correlation between heart failure and the subsequent risk of herpes zoster. BMC Infect Dis 2015; 15: 17, doi: 10.1186/s12879-015-0747-9.
84. Parameswaran GI, Drye AF, Wattengel BA, et al. Increased Myocardial Infarction Risk Following Herpes Zoster Infection. Open Forum Infect Dis 2023; 10(4): ofad137, doi: 10.1093/ofid/ofad137.
85. Curhan SG, Kawai K, Yawn B, et al. Herpes Zoster and Long-Term Risk of Cardiovascular Disease. J Am Heart Assoc 2022; 11(23): e027451, doi: 10.1161/JAHA.122.027451.
86. Kuo CC, Lee CT, Lee IM, et al. Risk of herpes zoster in patients treated with long-term hemodialysis: a matched cohort study. Am J Kidney Dis 2012; 59(3): 428–433, doi: 10.1053/j.ajkd.2011.10.049.
87. Schmidt SAJ, Langan SM, Pedersen HS, et al. Mood Disorders and Risk of Herpes Zoster in 2 Population-Based Case-Control Studies in Denmark and the United Kingdom. Am J Epidemiol 2018; 187(5): 1019–1028, doi: 10.1093/aje/kwx338.
88. Min C, Bang WJ, Oh DJ, et al. Association between Herpes Zoster and Osteoporosis: A Nested Case-Control Study Using a National Sample Cohort. Biomed Res Int 2019; 2019: 4789679, doi: 10.1155/2019/4789679.
89. Hsieh WC, Chen CH, Cheng YC, et al. The Risk of Herpes Zoster in Women with Polycystic Ovary Syndrome: A Retrospective Population-Based Study. Int J Environ Res Public Health 2022; 19(5): 3094, doi: 10.3390/ijerph19053094.
90. Ke DS, Hsu CY, Lin CL, et al. Herpes zoster in patients with sciatica. BMC Musculoskelet Disord 2020; 21(1): 813, doi: 10.1186/s12891-020-03847-5.
91. Zhang JX, Joesoef RM, Bialek S, et al. Association of physical trauma with risk of herpes zoster among Medicare beneficiaries in the United States. J Infect Dis 2013; 207(6): 1007–1011, doi: 10.1093/infdis/jis937.
92. Parikh R, Spence O, Giannelos N, et al. Herpes Zoster Recurrence: A Narrative Review of the Literature. Dermatol Ther (Heidelb) 2024; 14(3): 569–592, doi: 10.1007/s13555-024-01101-7.
93. Kim YJ, Lee CN, Lee MS, et al. Recurrence Rate of Herpes Zoster and Its Risk Factors: a Population-based Cohort Study. J Korean Med Sci 2018; 34(2): e1, doi: 10.3346/jkms.2019.34.e1.
94. Parikh R, Widenmaier R, Lecrenier N. A practitioner’s guide to the recombinant zoster vaccine: review of national vaccination recommendations. Expert Rev Vaccines 2021; 20(9): 1065–1075, doi: 10.1080/14760584.2021.1956906.
95. Lal H, Poder A, Campora L, et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study. Vaccine 2018; 36(1): 148–154, doi: 10.1016/j.vaccine.2017.11.019.
96. Izurieta HS, Wu X, Forshee R, et al. Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure. Clin Infect Dis 2021; 73(6): 941–948, doi: 10.1093/cid/ciab125.
97. The Australian Immunisation Handbook provides clinical advice for health professionals on the safest and most effective use of vaccines in their practice [cited 06.05.2025]. Available from URL: immunisationhandbook.health.gov.au.
98. Antczak A, Balcerzak M, Byliniak M, et al. Bariery i rozwiązania w dostępie do profilaktyki chorób zakaźnych. OPZCI: Warszawa, 2024 [cited 06.05.2025]. Available from URL: https://opzci.pl/materialy/ (in Polish).
99. Ankieta dotycząca błędnych przekonań na temat półpaśca przeprowadzona z udziałem 3500 osób dorosłych w wieku 50 i więcej lat w 12 krajach (Australia, Brazylia, Kanada, Chiny, Niemcy, Indie, Włochy, Japonia, Portugalia, Korea Południowa, Wielka Brytania, USA), Pollfish na zlecenie GSK. 18 sierpnia 2023 r. [cited 06.05.2025]. Available from URL: https://www.pollfish.com/blog/global-gsk-shingles-survey-insights/ (in Polish).
100. Grudziąż-Sękowska J, Sękowski K, Grześczyk-Nojszewska Z, et al. Public Awareness and Willingness to Vaccinate Against Herpes Zoster: A Nationwide Cross-Sectional Study in Poland. Vaccines (Basel) 2024; 12(12): 1393, doi: 10.3390/vaccines12121393.
101. Godeaux O, Kovac M, Shu D, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults? 50 years of age with a prior history of herpes zoster: a phase III, non-randomized, open-label clinical trial. Hum Vaccin Immunother 2017; 13: 1051–1058.
102. Lu A, Sun Y, Porco TC, et al. Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States. Ophthalmology 2021; 128(12): 1699–1707, doi: 10.1016/j.ophtha.2021.04.017.
103. Litt J, Cunningham AL, Arnalich-Montiel F, et al. Herpes Zoster Ophthalmicus: Presentation, Complications, Treatment, and Prevention. Infect Dis Ther 2024; 13(7): 1439–1459, doi: 10.1007/s40121-024-00990-7.
104. Walia A, Sun Y, Acharya NR. Risk of Herpes Zoster Ophthalmicus Recurrence After Recombinant Zoster Vaccination. JAMA Ophthalmol 2024; 142(3): 249–256, doi: 10.1001/jamaophthalmol.2023.6830.
105. American Academy of Ophtalmology Policy Statement Recommendations for Herpes Zoster Vaccine for Patients 50 Years of Age and Older [cited 06.05.2025]. Available from URL: https://www.aao.org/Assets/5b036a6b-9647-4200-adca-0021d8ca77a3/636718478713970000/hzv-policy-statement-2018-pdf.
106. FDA Requires a Warning about Guillain-Barré Syndrome (GBS) be Included in the Prescribing Information for Shingrix [cited 06.05.2025]. Available from URL: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-warning-about-guillain-barre-syndrome-gbs-be-included-prescribing-information-shingrix.
107. Goud R, Lufkin B, Duffy J, et al. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries. JAMA Intern Med 2021; 181(12): 1623–1630, doi: 10.1001/jamainternmed.2021.6227.
108. Kang JH, Sheu JJ, Lin HC. Increased risk of Guillain-Barré Syndrome following recent herpes zoster: a population-based study across Taiwan. Clin Infect Dis 2010; 51(5): 525–530, doi: 10.1086/655136.
109. Zhang S, Kim VHD, Grunebaum E. Pediatric herpes zoster: should I be concerned for immunodeficiency? A review. Front Pediatr 2025; 13: 1561339, doi: 10.3389/fped.2025.1561339.
110. Charakterystyka Produktu Leczniczego Varlilix [cited 06.05.2025]. Available from URL: https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/9225/characteristic (in Polish).
111. Charakterystyka Produktu Leczniczego Varivax [cited 06.05.2025]. Available from URL: https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/42067/characteristic (in Polish).
112. CDC Pink Book, Chapter 22: Varicella [cited 06.05.2025]. Available from URL: https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-22-varicella.html.
113. Weinmann S, Naleway AL, Koppolu P, et al. Incidence of Herpes Zoster Among Children: 2003–2014. Pediatrics 2019; 144(1): e20182917, doi: 10.1542/peds.2018-2917.
114. Bhattacharya A, Jan L, Burlak O, et al. Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine. NPJ Vaccines 2024; 9(1): 72, doi: 10.1038/s41541-024-00865-5 [published correction appears in NPJ Vaccines 2024; 9(1): 224, doi: 10.1038/s41541-024-01020-w].
115. Gershon AA, Breuer J, Cohen JI, et al. Varicella zoster virus infection. Nat Rev Dis Primers 2015; 1: 15016, doi: 10.1038/nrdp.2015.16.
116. Papaloukas O, Giannouli G, Papaevangelou V. Successes and challenges in varicella vaccine. Ther Adv Vaccines 2014; 2(2): 39–55, doi: 10.1177/2051013613515621.
117. Syed YY. Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster. Drugs Aging 2018; 35(12): 1031–1040, doi: 10.1007/s40266-018-0603-x.
118. Harbecke R, Cohen JI, Oxman MN. Herpes Zoster Vaccines. J Infect Dis 2021; 224(12 Suppl. 2): S429–S442, doi: 10.1093/infdis/jiab387.
Copyright: © 2025 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.